BioStock: Alligator Bioscience’s CSO presents CD40 portfolio at summit

Alligator Bioscience’s CD40 agonist mitazalimab has recently shown promising results in a second interim analysis of the OPTIMIZE-1 phase II study in pancreatic cancer. The results will be presented by CSO Peter Ellmark at the 3rd Annual Tumour Myeloid-Directed Therapies Summit in Boston. His presentation also features the company’s bispecific CD40/CEACAM5 antibody ATOR-4066 and its potential to induce strong anti-tumour response in patients with CEACAM5-expressing tumours. BioStock contacted Peter Ellmark to get to know more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/alligator-biosciences-cso-presents-cd40-portfolio-at-summit/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se